HC Wainwright & Co. Maintains Buy on Cytokinetics, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. maintains a Buy rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $94 to $90.
May 23, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Cytokinetics but lowers the price target from $94 to $90.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100